RxDoctor Payments Data

Anna Barrickman, APRN

Nurse Practitioner · Shelbyville, KYNPI 1891217527

Payments from drug & device makers

$1,802in general payments, 2019–2025

Across 92 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$460
  • Lilly USA, LLC$379
  • Pfizer$132
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$88
  • Abbott$83
  • AbbVie$63
  • plus $597 from 20 others

What the payments were for

  • Food & beverage$1,802100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,802 in reported general payments places this provider in the 75th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$50,842
Medicare patients
156
Services billed
738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide147$177,951
OzempicSemaglutide92$111,381
EliquisApixaban65$65,635
XareltoRivaroxaban23$21,290
WegovySemaglutide16$21,021
FarxigaDapagliflozin Propanediol21$19,537
TrintellixVortioxetine Hydrobromide23$17,296
JardianceEmpagliflozin11$17,047
Repatha SureclickEvolocumab19$15,953
Repatha SyringeEvolocumab14$12,944
SymbicortBudesonide/Formoterol Fumarate19$5,290
Desvenlafaxine Succinate ErDesvenlafaxine Succinate57$4,535
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$3,994
SteglatroErtugliflozin Pidolate11$3,668
PaxlovidNirmatrelvir/Ritonavir14$2,751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$379$177,951147 claims
Novo NordiskOzempic, Wegovy$460$132,402108 claims
PfizerEliquis, Paxlovid$132$68,38679 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$62$17,29623 claims
Boehringer IngelheimJardiance$29$17,04711 claims
MerckSteglatro$14$3,66811 claims
AbbVieSynthroid$63$2,35336 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Shelbyville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →